Jilin Provincial Cancer Hospital
Jilin Provincial Cancer Hospital
Zhang J.,Xinjiang Medical University |
Liu J.,Jilin Provincial Cancer Hospital |
Xu X.,Xinjiang Medical University |
Li L.,Xinjiang Medical University
Cancer Chemotherapy and Pharmacology | Year: 2017
Purpose: To investigate how curcumin alters the extracellular vesicles’ (EVs) capability to ship drug resistance in ovarian cancer. Methods: The EVs from cisplatin-resistant A2780cp cells with curcumin treatment (EVs-CU) or without curcumin treatment (EVs-N) were collected for lncRNA profiling. Curcumin’s effect on MEG3 promoter methylation and MEG3 expression were studied by MSP and qRT-PCR, respectively. The regulative effect of MEG3 on miR-214 expression and the functional role of EVs mediated transfer of miR-214 in cisplatin resistance were further investigated. Results: Curcumin weakened the EVs-N’s capability to induce drug resistance and induced significant changes of lncRNAs in the EVs. MEG3 is one of the most upregulated lncRNAs. Curcumin led to demethylation in the promoter region of MEG3 and 5-AZA-dC treatment restored MEG3 expression in a dose dependent manner. There were at least two binding sites between MEG3 and miR-214. MEG3 restoration by curcumin significantly reduced miR-214 in cells and in EVs. Functionally, miR-214 inhibition weakened the EVs-N’s capability to enhance chemoresistance, while miR-214 overexpression increased the capability of EVs-CU in inducing chemoresistance. Conclusion: Curcumin can restore MEG3 levels via demethylation. MEG3 upregulation can decrease EVs mediated transfer of miR-214 in ovarian cancer cells, thereby reducing drug resistance. © 2017 Springer-Verlag Berlin Heidelberg
Zhang S.,Jilin Provincial Cancer Hospital |
Liu J.,Jilin Provincial Cancer Hospital |
Cheng Y.,Jilin Provincial Cancer Hospital
Chinese Journal of Clinical Oncology | Year: 2017
Small cell lung cancer (SCLC) is a lethal malignancy characterized by rapid growth, early metastatic spread, and unfavorable survival outcomes. Optimizing treatment for patients with SCLC has been the focus for investigators. The emergence of precision medicine and personalized treatment brought significant breakthroughs into SCLC treatment and changed the therapeutic model. The development of molecular bioinformatics increased our understanding of complex molecular mechanisms of SCLC, and novel targets for personalized treatment have been developed. Clinical trials testing these targets are ongoing, which show the potential of personalized treatment for SCLC.
Liu Y.,Jilin Provincial Cancer Hospital |
Wang Y.,Jilin Provincial Cancer Hospital |
Liu X.,Jilin Provincial Cancer Hospital |
Zhu J.,Jilin Provincial Cancer Hospital |
And 4 more authors.
Cancer Research and Clinic | Year: 2017
Objective To analyze the efficacy and safety of different chemotherapy regimens for treatment of progressive patients with small cell lung cancer (SCLC) brain metastasis after radiotherapy. Methods 96 SCLC brain metastasis patients with progressive intracranial lesions after radiotherapy were divided into four groups: carmustine group (Group A, 28 cases), temozolomide group (Group B, 19 cases), topotecan group (Group C, 24 cases) and no chemotherapy group (Group D, 25 cases). Results In terms of brain metastases, there were no complete response cases in the whole groups. The rates of partial remission (PR), stable disease (SD) and progression of disease (PD) in Group A were 17.8 % (5/28), 53.6 % (15/28) and 28.6 % (8/28), respectively, the response rate (RR) of intracranial lesions was 17.9 % (5/28), and disease control (CR + PR + SD) rate was 71.4 % (20/28). The rates of PR, SD and PD in Group B were 15.8 % (3/19), 63.2 % (12/19) and 21.1 % (4/19), respectively, the RR of intracranial lesions was 15.8 % (3/19), and disease control rate was 78.9 % (15/19). The rates of PR, SD and PD in Group D were 8.3 % (2/24), 54.2 % (13/24) and 37.5 % (9/24), respectively, the RR rate of intracranial lesions was 8.3 % (2/24), and disease control rate was 62.5 % (15/24). In Group D, there was no response case, and 20 patients with PD (80.0 %) were found. The median progression-free survivals (PFSs) were (3.64±0.43) months, (4.68 ±0.49) months, (3.58 ±0.50) months, (2.60 ±0.31) months in Group A, B, C and D, respectively, and the median overall survivals (OSs) were (18.80±1.74) months, (18.76±1.85) months, (19.10±1.64) months and (9.64±0.84) months, respectively. The median OS of Group A, B or C was longer than that of Group D (P = 0.002). The differences of grade HI - IV hematologic toxicities among the four subgroups were not statistically different. Patients in Group B had better tolerance to nausea and vomit. In Group D, the central nervous system symptoms such as fatigue and headache occurred frequently. Conclusions The response rate and OS of SCLC brain metastasis patients with progressive intracranial lesions after radiotherapy are improved after chemotherapy, however, PFS is not significantly prolonged. The efficacies of carmustine, temozolomide and topotecan are similar in short and long term, besides, temozolomide shows less adverse events and a higher disease control rate. The application of chemotherapy that could penetrate the blood-brain barrier can improve the efficacy on SCLC brain metastasis patients with progressive intracranial lesions after radiotherapy with well tolerance.
Wu H.,Jilin UniversityJilin Province |
Deng D.,Jilin Provincial Cancer Hospital |
Cao H.,Jilin UniversityJilin Province |
Song Z.,Jilin UniversityJilin Province |
Qin L.,Jilin UniversityJilin Province
International Journal of Clinical and Experimental Medicine | Year: 2017
Mesenchymal stromal cells (MSCs) transfer has emerged as a new therapeutic modality for acute myocardial infarction (AMI), but the benefits and safety profile still remain controversial. We performed a meta-analysis to assess the efficacy and safety of MSCs transplantation in patients with AMI based on published randomized controlled trials (RCTs). A systematic literature search of Pub Med, EMBASE, and the Cochrane library from 1985 to 2016 was conducted. We identified RCTs involving subjects with AMI receiving MSCs therapy and following up for at least 3 months for inclusion. Pooled analyses were conducted using random effects models. The defined end points were left ventricular ejection fraction (LVEF), left ventricular end-diastolic volumes (LVEDV) and left ventricular end-systolic volumes (LVESV), and major adverse cardiac event rates (MACEs). Seven trials with a total of 435 participants were included. Overall, MSCs therapy improved LVEF by 4.79% (95% confidence interval [CI] 2.12-7.46, P=0.0004), compared with the controls. There were trends toward reduced LVEDV and LVESV, but the differences were not significant (P=0.22 and P=0.09). Meta-analysis of the RCTs did not detect an association between MSCs and MACEs, all-cause death, heart failure, in-stent thrombosis, recurrent myocardial infarction, arrhythmia or re-hospitalization. In addition, Subgroup analysis also revealed greater increase in LVEF in favor of MSCs regarding duration of <6 months, 6 months and 12 months (P<0.00001, P=0.0003, P=0.0005, respectively) but not for >12 months (P=0.17) no matter what measurement was used. Based on the current clinical trials, transplantation of MSCs for patients with AMI induces a significant increase in LVEF and is safe in short-term follow-up. © 2017, E-Century Publishing Corporation. All rights reserved.
PubMed | Eli Lilly and Company, Tongji University, Shanghai JiaoTong University, Jilin Provincial Cancer Hospital and 4 more.
Type: Journal Article | Journal: Clinical lung cancer | Year: 2016
Pemetrexed plus platinum has become a standard of care in first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer. However, elderly lung cancer patients are generally understudied and undertreated in clinical practice in East Asia because of safety concerns. This analysis aimed to provide a picture of the clinical benefit of pemetrexed/platinum in the first-line setting for elderly (age 65 years) East Asian patients.Individual patient data from 3 randomized controlled phase 3 trials that enrolled East Asian patients were analyzed in this meta-analysis.In elderly East Asian patients (63 in the pemetrexed/platinum group and 42 in the control group), pemetrexed/platinum treatment achieved more benefits compared to other platinum-based doublets, including better overall response rate (32.8% vs. 7.5%), favorable progression-free survival (not statistically significant in adjusted hazard ratio), and significantly longer (3.15 vs. 1.54 months) survival without drug-related grade 3/4 toxicity. Overall survival was numerically prolonged (16.33 vs. 13.77 months; not statistically significant). These benefit trends were similar to those in all-age East Asian patients. In elderly East Asians, pemetrexed/platinum treatment was also associated with a lower incidence rate of drug-related grade 3/4 adverse events. The adverse event profile was similar to that in all-age East Asians. There were no unexpected adverse events.Pemetrexed/platinum had good efficacy and also resulted in better overall response and tolerability than other platinum-based doublets as first-line treatment in nonsquamous non-small cell lung cancer in elderly East Asians, which was consistent with data observed in all-age East Asians.
PubMed | Chinese Academy of Sciences, Shanghai First Peoples Hospital, 81 Hospital of Peoples Liberation Army, Jilin Provincial Cancer Hospital and 8 more.
Type: | Journal: BMC cancer | Year: 2016
The ToGA study showed that trastuzumab plus chemotherapy prolonged median survival in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer. Among chemotherapy options, oxaliplatin might be as effective as cisplatin but has shown to be more tolerable. To further improve treatment options for patients with advanced gastric cancer, we initiated a study to evaluate the efficacy and safety of trastuzumab plus oxaliplatin/capecitabine in patients with HER2-positive advanced gastric cancer.CGOG1001 was an open-label, multicenter, prospective phase II study. Patients with chemotherapy-naive HER2-positive advanced gastric cancer were eligible. Trastuzumab was administered at a loading dose of 8 mg/kg followed by 6 mg/kg infusion every 3 weeks (q3w). Oxaliplatin was administrated as a 130 mg/m(2) infusion, q3w, for up to 6 cycles. Capecitabine 1000 mg/m(2) was given orally twice daily on days 1-14 followed by a 7-day rest interval. Trastuzumab and capecitabine were continued until disease progression or intolerable toxicity. The primary endpoint was objective response rate. Simon two-stage design (H0 = 40%, H1 = 60%, = 0.05, = 0.2) by Response Evaluation Criteria In Solid Tumors 1.0 was applied.Fifty-one patients were enrolled. Confirmed response was recorded in 46 patients. One patient achieved complete response and 33 patients achieved partial response (response rate 34/51 [66.7%] in the intent-to-treat population). Median follow-up time was 28.6 months, with a median progression-free survival of 9.2 months (95% confidence interval [CI]: 6.5-11.6) and a median overall survival (OS) of 19.5 months (95% CI: 15.5-26.0). Patients with a HER2/CEP17 ratio of greater than five achieved improved OS (20.9 vs 19.5 months, p = 0.001). The most common adverse events of grade 3 or above were thrombocytopenia (21.6%), neutropenia (13.7%), anemia (5.9 %) and leucopenia (3.9%).The addition of trastuzumab to oxaliplatin/capecitabine was well tolerated and the results demonstrated encouraging efficacy.ClinicalTrials.gov NCT01364493.
PubMed | Affiliated Hospital of the Academy of Military Medical science, Jilin Provincial Cancer Hospital, Zhejiang Cancer Hospital and Shenyang University
Type: Clinical Trial | Journal: Future oncology (London, England) | Year: 2016
As data on the use of circulating tumor cells (CTCs) to predict patient outcomes in extensive-stage small-cell lung cancer (ES-SCLC) remain inconclusive, we investigated the clinical value of CTC determination in an open-label, multicenter study of 91 patients with newly diagnosed ES-SCLC.Blood CTC counts were determined using the CellSearch system at baseline, after the second cycle of chemotherapy, and on disease progression.Following the second cycle of treatment, CTC numbers and the change in CTCs were strong, significant and independent indicators for both progression-free survival and overall survival in ES-SCLC. The CTC change was associated with both refractory disease (response to initial therapy 3 months) and sensitive disease (response to initial therapy >3 months).
Wang H.,Jilin Provincial Cancer Hospital |
Liu Y.,Jilin Provincial Cancer Hospital |
Wang X.,Jilin Provincial Cancer Hospital |
Liu D.,Jilin Provincial Cancer Hospital |
And 5 more authors.
Cancer | Year: 2015
BACKGROUND: The objective of this study was to determine the efficacy and safety of locoregional therapy (LRT) combined with arsenic trioxide (As2O3) treatment in primary hepatocellular carcinoma (HCC) patients. METHODS: One hundred twenty-five primary HCC patients were recruited for a randomized controlled study. Patients were randomly divided into group A (n = 61) and group B (n = 64). All patients received transarterial chemoembolization. Group A patients were given As2O3 at 10 mg/d for 4 courses (21 days per course) with a 2-week interval between courses. Survival times, therapeutic responses, extrahepatic metastases, and adverse events were recorded. RESULTS: A better therapeutic response was found in group A patients, as shown by higher objective response rate (ORR) and clinical benefit rate (CBR) values in group A versus group B (ORR, 81.96% [95% confidence interval (CI), 72.32%-91.62%] vs 59.37% [95% CI, 47.34%-71.41%], χ2 = 7.650, P < .05; CBR, 95.08% [95% CI, 89.66%-100.00%] vs 81.25% [95% CI, 71.69%-90.81%], χ2 = 5.659, P < .05). There were fewer patients with extrahepatic metastases in group A versus group B (group A, 6 cases or 9.84% [95% CI, 2.36%-17.31%]; group B, 12 cases or 18.75% [95% CI, 9.19%-28.31%]). The survival rate for group A patients was significantly higher than that for group B patients (P < .05). No significant differences were found between the 2 groups in terms of hematology or digestive system, liver, or kidney dysfunction except for facial and limb edema. CONCLUSIONS: LRT combined with As2O3 treatment prevents extrahepatic metastasis and prolongs the survival time for primary HCC patients. Cancer 2015;121:2917-2925. © 2015 American Cancer Society.
PubMed | Jilin Provincial Cancer Hospital
Type: Journal Article | Journal: Cancer | Year: 2015
The objective of this study was to determine the efficacy and safety of locoregional therapy (LRT) combined with arsenic trioxide (As2 O3 ) treatment in primary hepatocellular carcinoma (HCC) patients.One hundred twenty-five primary HCC patients were recruited for a randomized controlled study. Patients were randomly divided into group A (n=61) and group B (n=64). All patients received transarterial chemoembolization. Group A patients were given As2 O3 at 10 mg/d for 4 courses (21 days per course) with a 2-week interval between courses. Survival times, therapeutic responses, extrahepatic metastases, and adverse events were recorded.A better therapeutic response was found in group A patients, as shown by higher objective response rate (ORR) and clinical benefit rate (CBR) values in group A versus group B (ORR, 81.96% [95% confidence interval (CI), 72.32%-91.62%] vs 59.37% [95% CI, 47.34%-71.41%], (2) =7.650, P<.05; CBR, 95.08% [95% CI, 89.66%-100.00%] vs 81.25% [95% CI, 71.69%-90.81%], (2) =5.659, P<.05). There were fewer patients with extrahepatic metastases in group A versus group B (group A, 6 cases or 9.84% [95% CI, 2.36%-17.31%]; group B, 12 cases or 18.75% [95% CI, 9.19%-28.31%]). The survival rate for group A patients was significantly higher than that for group B patients (P<.05). No significant differences were found between the 2 groups in terms of hematology or digestive system, liver, or kidney dysfunction except for facial and limb edema.LRT combined with As2 O3 treatment prevents extrahepatic metastasis and prolongs the survival time for primary HCC patients.
PubMed | Jilin Provincial Cancer Hospital
Type: Journal Article | Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology] | Year: 2016
To analyze whether there are differences in the efficacy and clinical outcomes to first-line tyrosine kinase inhibitors (TKI) therapy in Chinese patients with metastatic non-small-cell lung cancer (NSCLC) harboring different subtypes of epidermal growth factor receptor (EGFR) mutations.A retrospective analysis was made on the clinical data of stage B or NSCLC patients who were diagnosed by histology and received EGFR mutation test, in order to confirm if there is any difference between the therapeutic effects of TKIs as first-line therapy and the prognosis.A total of 165 patients harboring EGFR exon 19 deletion (19del, n=71), exon 21 L858R mutation (L858R, n=80) or uncommon sensitive mutation (n=14) were treated with EGFR-TKIs for first-line treatment. The comparison among different groups of common types of sensitive mutations revealed that the objective response rate (ORR) of group 19del and group L858R were 57.8% and 45.0%, respectively (P=0.113). The disease control rate (DCR) was 93.0% and 93.8%, respectively (P=0.158). However, the ORR and DCR of uncommon sensitive mutation were 35.7% and 78.6%, which were significantly lower than that of the group 19del (P=0.035) and group L858R (P=0.020). The median progression-free survival (PFS) of group 19del, group L858R and uncommon sensitive mutation were 14.0 months, 7.8 months and 5.1 months, respectively (P=0.001). The median PFS of the group 19del was significantly longer than that of the group L858R (P=0.009). The median overall survival (OS) of these three groups had significant difference (22.8, 15.2 and 10.0 months) (P=0.048). But those of group 19del and group L858R were similar (P=0.152). The multivariate analysis indicated that ECOG-PS (P=0.030), cigarette smoking (P=0.013) and EGFR mutation types (P=0.034) are independent prognostic factors of OS.For Chinese NSCLC patients with different types of sensitive mutation, there are differences between their efficacy and prognosis of EGFR-TKIs as first-line treatment. The PFS of group 19del is obviously longer than that of other types of sensitive mutations, but have no significant differences in OS. The PFS and OS of patients with common types of sensitive mutation are better than those with uncommon sensitive mutation.